Spinal Cord Homogenate Induced EAE in (BALB/c x SJL)F1 Mice
Hooke runs most commonly-used EAE models. Click here for an overview of EAE and a list of models offered.
This direct EAE model is induced by immunization with mouse whole spinal cord homogenate emulsified in CFA in crossbred (BALB/c x SJL)F1 mice, followed by a single injection of pertussis toxin.
It was once commonly used to evaluate efficacy and equivalence of generic glatiramer acetate [1], however our experience (with concurrence from the FDA) is that other models are better suited for that purpose.
Copaxone (Teva Pharmaceuticals) is used as a positive control and reference compound. Treatment is prophylactic, the model is 28 days long.
Glatiramer acetate potency can alternatively be evaluated by analysis of cytokine production by T cells isolated from immunized mice; Hooke offers ELISA, cytokine bead assay (CBA), and Luminex assays, which are all suitable for this analysis.
Please contact Hooke at or with questions or for a quotation.
Typical results in this model
Spinal cord homogenate induced EAE in (BALB/c x SJL)F1 mice
F1_Proph_R20131218-H2_Scores.png)
F1_Proph_R20131218-H2_Weights.png)
| Treatment | Median day of onset |
p value (onset) |
MMS ± SEM |
p value (MMS) |
Relapse incidence | p value (incidence) |
|---|---|---|---|---|---|---|
| Vehicle | 10.0 | 3.50 ± 0.19 | 81.8% | |||
| Glatiramer acetate | 13.0 | <0.0001 | 1.83 ± 0.33 | 0.0015 | 33.3% | 0.0162 |
| Treatment | Relapse MMS ± SEM |
p value (relapse MMS) |
End score ± SEM |
p value (end score) |
End weight (%) ± SEM |
p value (end weight) |
|---|---|---|---|---|---|---|
| Vehicle | 2.83 ± 0.32 | 1.92 ± 0.43 | 91.6 ± 1.8 | |||
| Glatiramer acetate | 0.96 ± 0.36 | 0.0015 | 0.79 ± 0.34 | 0.0172 | 103.8 ± 2.3 | 0.0004 |
Tissue collection and end-of-study analysis
Hooke offers an extensive set of tissue collection and analysis options. Click here for more information.
_150px.jpg)